The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders.
Andrey Alexandrovitch KibitovElena Mikhaylovna KiryanovaLudmila Ivanovna SalnikovaIrina Vladimirovna BureAlexander Borisovitch ShmuklerAlexander Olegovitch KibitovPublished in: Drug metabolism and personalized therapy (2022)
Our results highlight the importance of using both pharmacokinetic and pharmacodynamic genetic markers for predicting haloperidol treatment response to personalize schizophrenia spectrum disorders treatment.